YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK–STAT3 Signaling

Gastroenterology

Volumn 151, Issue 3, 2016, Pages 526-539

  Gruber, Ralph ^a   Panayiotou, Richard ^a   Nye, Emma ^a   Spencer Dene, Bradley ^a   Stamp, Gordon ^a   Behrens, Axel ^a,b  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Inflammation; Mouse Model; Pancreatic Cancer Progression; PanINs

Indexed keywords

CERULETIDE; CONNECTIVE TISSUE GROWTH FACTOR; CRE RECOMBINASE; CYSTEINE RICH PROTEIN 61; GLYCOPROTEIN GP 130; INTERLEUKIN 13 RECEPTOR ALPHA1; JANUS KINASE; K RAS PROTEIN; LEUKEMIA INHIBITORY FACTOR RECEPTOR; STAT3 PROTEIN; TAMOXIFEN; TAZ PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG; KRAS2 PROTEIN, MOUSE; PHOSPHOPROTEIN; PROTEIN P21; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STAT3 PROTEIN, MOUSE; TAZ PROTEIN, MOUSE; YAP PROTEIN, MOUSE;

ACINAR CELL; ACUTE PANCREATITIS; ADULT; ADULT ANIMAL; ALLELE; AMOTL2 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKRD1 GENE; ARTICLE; BINDING SITE; CARCINOGENESIS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME PHOSPHORYLATION; GENE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC TISSUE; PRIORITY JOURNAL; PROMOTER REGION; RAT; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; UPREGULATION; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; GENETICS; METABOLISM; MUTATION; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS; PATHOLOGY; RISK FACTOR;

ACINAR CELLS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARCINOGENESIS; JANUS KINASES; MICE; MUTATION; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RISK FACTORS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84995390669     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.05.006     Document Type: Article

References (47)

1. 1 Guerra, C., Schuhmacher, A.J., Canamero, M., et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11 (2007), 291–302.
2. 2 Jensen, J.N., Cameron, E., Garay, M.V., et al. Recapitulation of elements of embryonic development in adult mouse pancreatic regeneration. Gastroenterology 128 (2005), 728–741.
3. 3 Means, A.L., Meszoely, I.M., Suzuki, K., et al. Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development 132 (2005), 3767–3776.
4. 4 Reichert, M., Rustgi, A.K., Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest 121 (2011), 4572–4578.
5. 5 Hruban, R.H., Adsay, N.V., Albores-Saavedra, J., et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25 (2001), 579–586.
6. 6 Biankin, A.V., Waddell, N., Kassahn, K.S., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491 (2012), 399–405.
7. 7 DiGiuseppe, J.A., Hruban, R.H., Offerhaus, G.J., et al. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 144 (1994), 889–895.
8. 8 Kanda, M., Matthaei, H., Wu, J., et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142 (2012), 730–733 e9.
9. 9 Eser, S., Schnieke, A., Schneider, G., et al. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer 111 (2014), 817–822.
10. 10 Bardeesy, N., DePinho, R.A., Pancreatic cancer biology and genetics. Nat Rev Cancer 2 (2002), 897–909.
11. 11 Carriere, C., Young, A.L., Gunn, J.R., et al. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem Biophys Res Commun 382 (2009), 561–565.
12. 12 Hofbauer, B., Saluja, A.K., Lerch, M.M., et al. Intra-acinar cell activation of trypsinogen during caerulein-induced pancreatitis in rats. Am J Physiol 275 (1998), G352–G362.
13. 13 Morris, J.P.t, Cano, D.A., Sekine, S., et al. Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J Clin Invest 120 (2010), 508–520.
14. 14 Shi, G., DiRenzo, D., Qu, C., et al. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia. Oncogene 32 (2013), 1950–1958.
15. 15 Ji, B., Tsou, L., Wang, H., et al. Ras activity levels control the development of pancreatic diseases. Gastroenterology 137 (2009), 1072–1082 1082 e1–e6.
16. 16 Hingorani, S.R., Wang, L., Multani, A.S., et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 (2005), 469–483.
17. 17 Siveke, J.T., Einwachter, H., Sipos, B., et al. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 12 (2007), 266–279.
18. 18 Daniluk, J., Liu, Y., Deng, D., et al. An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 122 (2012), 1519–1528.
19. 19 Kapoor, A., Yao, W., Ying, H., et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158 (2014), 185–197.
20. 20 Zhang, W., Nandakumar, N., Shi, Y., et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal, 7, 2014, ra42.
21. 21 Kranz, A., Fu, J., Duerschke, K., et al. An improved Flp deleter mouse in C57Bl/6 based on Flpo recombinase. Genesis 48 (2010), 512–520.
22. 22 Ulmasov, B., Oshima, K., Rodriguez, M.G., et al. Differences in the degree of cerulein-induced chronic pancreatitis in C57BL/6 mouse substrains lead to new insights in identification of potential risk factors in the development of chronic pancreatitis. Am J Pathol 183 (2013), 692–708.
23. 23 Yimlamai, D., Christodoulou, C., Galli, G.G., et al. Hippo pathway activity influences liver cell fate. Cell 157 (2014), 1324–1338.
24. 24 He, T.C., Zhou, S., da Costa, L.T., et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95 (1998), 2509–2514.
25. 25 Gruber, R., Zhou, Z., Sukchev, M., et al. MCPH1 regulates the neuroprogenitor division mode by coupling the centrosomal cycle with mitotic entry through the Chk1-Cdc25 pathway. Nat Cell Biol 13 (2011), 1325–1334.
26. 26 Subramanian, A., Tamayo, P., Mootha, V.K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102 (2005), 15545–15550.
27. 27 Miyamoto, Y., Maitra, A., Ghosh, B., et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3 (2003), 565–576.
28. 28 Corcoran, R.B., Contino, G., Deshpande, V., et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 71 (2011), 5020–5029.
29. 29 Fukuda, A., Wang, S.C., Morris, J.P.t, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19 (2011), 441–455.
30. 30 George, N.M., Day, C.E., Boerner, B.P., et al. Hippo signaling regulates pancreas development through inactivation of Yap. Mol Cell Biol 32 (2012), 5116–5128.
31. 31 Hingorani, S.R., Petricoin, E.F., Maitra, A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4 (2003), 437–450.
32. 32 Zhao, B., Wei, X., Li, W., et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21 (2007), 2747–2761.
33. 33 Lei, Q.Y., Zhang, H., Zhao, B., et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 28 (2008), 2426–2436.
34. 34 Huang, D.W., Sherman, B.T., Lempicki, R.A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4 (2009), 44–57.
35. 35 Lesina, M., Kurkowski, M.U., Ludes, K., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19 (2011), 456–469.
36. 36 Mahoney, W.M. Jr., Hong, J.H., Yaffe, M.B., et al. The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. Biochem J 388 (2005), 217–225.
37. 37 ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489 (2012), 57–74.
38. 38 Home, P., Saha, B., Ray, S., et al. Altered subcellular localization of transcription factor TEAD4 regulates first mammalian cell lineage commitment. Proc Natl Acad Sci U S A 109 (2012), 7362–7367.
39. 39 Eser, S., Reiff, N., Messer, M., et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 23 (2013), 406–420.
40. 40 Suzuki, S., Miyasaka, K., Jimi, A., et al. Induction of acute pancreatitis by cerulein in human IL-6 gene transgenic mice. Pancreas 21 (2000), 86–92.
41. 41 Taniguchi, K., Wu, L.W., Grivennikov, S.I., et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 519 (2015), 57–62.
42. 42 Chen, D., Sun, Y., Wei, Y., et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med 18 (2012), 1511–1517.
43. 43 Hong, X., Nguyen, H.T., Chen, Q., et al. Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover. EMBO J 33 (2014), 2447–2457.
44. 44 Reddy, B.V., Irvine, K.D., Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins. Dev Cell 24 (2013), 459–471.
45. 45 Lin, L., Sabnis, A.J., Chan, E., et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet 47 (2015), 250–256.
46. 46 Azzolin, L., Panciera, T., Soligo, S., et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 158 (2014), 157–170.
47. 47 Cordenonsi, M., Zanconato, F., Azzolin, L., et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147 (2011), 759–772.